Communicating Human Papillomavirus Vaccine With Japanese Parents and Caregivers With Daughters Aged 12-18
Launched by THE UNIVERSITY OF HONG KONG · Apr 2, 2024
Trial Information
Current as of August 19, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This study will implement an experiment as a sixteen-arm randomized controlled trial in an online survey environment. Before the experiment, participants, who are Japanese caregivers with daughters aged 12-18 who have not received an HPV vaccine, will first answer a pre-experiment survey. The survey will collect information on participants' socio-demographic data and key decision-making factors for HPV vaccine acceptance and confidence. Then, the study will randomly assign the participants to view one digital communication message using a 2 × 2 × 2 × 2 between-person factorial experiment on...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Female adult caregivers, older than 20, with daughters aged 12-18 who have received none or only one shot of HPV vaccine.
- Exclusion Criteria:
- • Caregivers who do not agree to participate in survey, experiment, or both.
- • Caregivers with daughters who have already received two or more HPV vaccines.
About The University Of Hong Kong
The University of Hong Kong (HKU) is a leading research institution dedicated to advancing medical knowledge and improving healthcare outcomes through innovative clinical trials. With a commitment to excellence in research and education, HKU collaborates with various stakeholders, including healthcare providers and industry partners, to conduct rigorous and ethically sound clinical studies. The university's diverse expertise and state-of-the-art facilities enable it to explore a wide range of therapeutic areas, contributing to the global pursuit of scientific advancement and the development of novel treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, , United Kingdom
Patients applied
Trial Officials
Leesa Lin, PhD
Principal Investigator
London School of Hygiene and Tropical Medicine
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported